C₁₈H₁₄BrN₅O₆PS•Na; MW 562.3; λ_max 256 nm; ε 40000; sodium salt, purity > 99% HPLC. For other salt forms please inquire. Membrane-permeant inhibitor of the retinal type cGMP-gated ion channel (cGMP antagonist) but activator of cyclic GMP-dependent protein kinase I α and I ß (cGMP agonist). Suitable for distinction between kinase and ion channel mediated effects. Resistant against mammalian cyclic nucleotide-dependent phosphodiesterases, no metabolic side effects. More lipophilic and membrane-permeant compared to Sp-8-pCPT-cGMPS (Cat. No. C 014). Detailed technical information and updated reference list available on request. Reference: Butt et. al., Br. J. Pharmacol., 116, 3110 - 3116 (1995).

Protected under patents US 5,625,056, DE 42 17679 & DE 3802865.4 issued or licensed exclusively to BIOLOG LSI